Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Shapely

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Shapely head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 318 · Grade C

Shapely

Visit Shapely Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 63 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make Shapely a bad call — it's best for eligible patients in california, florida, new york or texas who want provider and dietitian visits and can budget separately for medication. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
40
Supply Reliability
95
78
Transparency
90
63
Access Breadth
93
42
Clinical Oversight
92
92
Track Record
88
77
CoreAge RxBrief Score 94 · 63Shapely

Price, coverage & the tracker

CoreAge RxShapely
Brief Score94/100 (A)63/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Medication + required care membership

Monthly drug: $139 low-mid dose/$179 high dose. Three-month starter/refill $297; high-dose $477. Self-pay membership $99/month, $49 first month, extra.

Labs excluded from care fee, typically insurance-covered or $75 as advertised. Full selected treatment, patient cancellation and package-refund calculation unconfirmed.

Full price details

Compounded semaglutide offered; complete selected-plan total unknown; three-month starter/refill package $297 or high-dose $477 plus required membership; monthly medication $139 low-mid dose or $179 high dose

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Medication + required care membership

Monthly drug: $249 low-mid dose/$299 high dose. Three-month starter $498, refill $597, high-dose $837, plus required membership.

Self-pay care $99/month, $49 first month; medication costs extra. Eligibility listed for CA, FL, NY and TX. Confirm package supply and refund terms.

Full price details

Compounded tirzepatide offered; complete selected-plan total unknown; three-month starter $498, refill $597 or high-dose $837 plus required membership; monthly medication $249 low-mid dose or $299 high dose

CoverageUS only; restrictions by state, confirmed at intakeCalifornia, Florida, New York and Texas for adults18+ under current medication-page eligibility FAQ; verify insurance and treatment eligibility
Brand-name accessNot confirmedCurrent catalog advertises oral Wegovy, Foundayo and named injectable brands; medication coverage and costs are separate from membership and require prescription/insurance review.
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

Shapely: Self-pay care is $99 monthly, $49 first month, plus medication. Three-month drug totals vary by dose and plan. Four-state eligibility applies; obtain the patient cancellation and refund agreement.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.